Press releases

2021-12-28

Eevia Health Plc, ("Eevia" or "The Company"), has received a large sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.

The sales value of this order is c.335,000 EUR and the product is Feno-Myrtillus 25 bilberry extract. The order is expected to create repeat sales of this product going forward.

2021-11-19

Eevia Health Plc (" Eevia" or" The Company") has concluded a human clinical study of the effects of Eevia's branded ingredient Feno-Chaga® Organic on Upper-Respiratory Tract Infections (URTIs) and Psychological Mood State with positive and promising results.

2021-11-16
Regulatory

The Board and CEO of Eevia Health Plc now present the Interim Report for the third quarter of 2021, covering the period 1 July through 30 September 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com

2021-11-12
Regulatory

Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 9th of December, 2021 at 1.00 pm at the main office of Eevia Health Plc in Koulukatu 14, Seinäjoki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12.30 pm.

2021-11-11
Regulatory

This is a correction to press release published 10 November, 2021 where the press release lacked a reference to the EU's Market Abuse Regulation (MAR).

The Board of Directors of Eevia Health Plc (publ) ("Eevia" or the "Company") has resolved, subject to the approval by shareholders at an Extraordinary General Meeting (the "EGM"), on a directed new issue of 2,061,856 shares at a subscription price of SEK 9.70 per share (the "Directed Share Issue"), which is expected to raise proceeds to the Company of SEK 20 million before issue costs. The proceeds will primarily be used for investments in increased capacity to better be able to meet current and future demand.

2021-11-10

The Board of Directors of Eevia Health Plc (publ) ("Eevia" or the "Company") has resolved, subject to the approval by shareholders at an Extraordinary General Meeting (the "EGM"), on a directed new issue of 2,061,856 shares at a subscription price of SEK 9.70 per share (the "Directed Share Issue"), which is expected to raise proceeds to the Company of SEK 20 million before issue costs. The proceeds will primarily be used for investments in increased capacity to better be able to meet current and future demand.

2021-10-29

Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from a leading organic supplement brand for supply of the Fenoprolic® 70 Organic (organic pine bark extract). The sales value of this start order is c.65,000 EUR, but the customer has a strong record on new product launches, and it is therefore expected to create repeat sales of this product going forward.  

1
2
3
4